ArticlePloS one2011

Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.

Silvia Catellani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.